Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

AudioCure Pharma GmbH. (5/22/17). "Press Release: AudioCure Appoints Dr. Reimar Schlingensiepen as CEO". Berlin.

Organisations Organisation AudioCure Pharma GmbH
  Organisation 2 MED-EL Elektromedizinische Geräte GmbH
Products Product AC102 (AudioCure)
  Product 2 drug development
Persons Person Schlingensiepen, Reimar (AudioCure Pharma 201508–COO before Jado 2010– CEO consultant + Antisense Pharma COO/CFO)
  Person 2 Rommelspacher, Hans (AudioCure Pharma GmbH 201705– CSO before CEO + Founder + Professor at Charité Berlin)

> Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO.

> Rommelspacher will continue as CSO.

> AudioCure recently secured funding of about 9 million euros in a Series A financing round from Austrian MED-EL Elektromedizinische Geräte GmbH, German investor High-Tech Gruenderfonds and private investors.

AudioCure, a German pharmaceutical company focusing on the development of treatments for hearing disorders, announced today that it has appointed Dr. Reimar Schlingensiepen as CEO.

Dr. Schlingensiepen has been with AudioCure as COO since July 2015. During that time, he has successfully reshaped the company and carved out the recent series A financing round of about 9 million euros. He takes over from Prof. Hans Rommelspacher, who will continue as CSO. “With Reimar´s deep commitment to AudioCure, his proven track record and over 20 years of experience in the biopharmaceutical industry spanning preclinical, clinical and product development, I could not have wished for a better person for the job of CEO,” said Prof. Rommelspacher.

Since 2008, Dr. Schlingensiepen has worked as entrepreneur and manager in the fields of biopharmaceutical development, med-tech and diagnostics. He co-founded a number of high-tech companies, where he held several management positions. In addition to his leadership and biopharmaceutical expertise, he brings to AudioCure substantial experience in manufacturing, marketing and finance. It is of great advantage to AudioCure that, as a medical doctor, Dr. Schlingensiepen also conducted a variety of clinical trials in oncology, immunology and neurology.

With AudioCure, Dr. Schlingensiepen´s immediate goal is to steer the company’s first in class front-runner molecule AC102 through its formal preclinical development. This is a prerequisite for the clinical development, which is planned in patients with auditory disorders including acute hearing loss and acute tinnitus.

“With the proof of principle for AC102 accomplished under the leadership of Prof. Rommelspacher, this is an exciting time in AudioCure’s development. We hold a gem in our hands with enormous potential for patients suffering from auditory disorders,” said Dr. Schlingensiepen. “In sharing responsibilities, Hans and I can continue on our seamless path to the clinic. I am very much looking forward to leading an AudioCure team that recognizes the unique opportunity we have to help transform the treatment landscape for hearing impairments.”

Dr. Reimar Schlingensiepen (left), the newly appointed CEO of AudioCure Pharma GmbH, takes over from Prof. Hans Rommelspacher, founder of the company, who continues as CSO.

Notes to Editor

About AudioCure

AudioCure Pharma GmbH is a pharmaceutical R&D company headquartered in Germany and founded by Prof. Hans Rommelspacher, MD and CSO. As the former head of the Department of Clinical Neurobiology in the Psychiatric Clinic at the Charité University, Berlin, Prof. Rommelspacher has extensive experience in neuroprotection and treatments for neurodegenerative disorders. It is Prof. Rommelspacher’s scientific expertise and lifelong dedication to neuroscience that led to the discovery of AC102, the company´s front-runner molecule.

Hearing impairment affects patients in many ways, often causing difficulties acquiring spoken language and limiting job opportunities, but also leading to social withdrawal, isolation and depression1. As approximately 20% of the population over the age of 14 suffers from a hearing impairment, more than 14 million people are affected in Germany alone2. Hearing loss also presents a significant economic burden, reflected by an estimated loss in gross domestic product of up to 2% in developed countries.

AudioCure’s preclinical models have demonstrated the unique potential of AC102 to tackle all three crucial types of cells of the inner ear affected by hearing loss: the inner hair cells, the outer hair cells and the acoustic nerve. By protecting and restoring the cellular key players that are critical to the hearing process, the therapeutic approach of AudioCure goes beyond treating symptoms to tackle the root cause of hearing loss.


1. Prevention of noise-induced hearing loss. WHO report, Geneva 1997
2. Deutscher Schwerhörigenbund e.V.

> For further information on AudioCure, please see our Notes to the Editor
> Press Release English (PDF): Audiocure CEO 22 May 2017

Contact AudioCure

AudioCure Pharma GmbH
Frauke Luers
Schlegelstr. 9
D-10115 Berlin · Germany
Tel.: +49 30 2218 39714

Record changed: 2023-06-05


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top